Ajanta Pharma Ltd

Ajanta Pharma Share Pledge

Aayush Agrawal (Trustee of Aayush Agrawal Trust) has released a pledge on 1,736,353 equity shares of Ajanta Pharma Limited. This follows loan repayment.

Ajanta Pharma Share Pledge

Promoter Aayush Agrawal Trust released pledge on 9.76 lakh shares and created a new pledge on 9.20 lakh shares of Ajanta Pharma Limited.

Ajanta Pharma Share Pledge

Promoter Ravi Agrawal, as trustee of Ravi Agrawal Trust, released a pledge on 54,796 equity shares of Ajanta Pharma Limited due to excess pledge.

Ajanta Pharma Earnings Call Transcript: Key Takeaways

Ajanta Pharma reports strong Q1 FY27 results, but management remains cautious about sustainability, guiding for normalization in the US and acknowledging geopolitical headwinds in Asia.

Call

Guides 18% growth

Ajanta Pharma Employee Stock Options

Ajanta Pharma Limited has allotted 23,400 equity shares following the exercise of employee stock options. Consequently, the company's paid-up share capital increased to Rs. 24.99 Crore.

Ajanta Pharma Dividend

Ajanta Pharma Limited has fixed August 5, 2026, as the record date. This date determines shareholder eligibility for the payment of the first interim dividend.

Ajanta Pharma Q1 FY27 Results: Net Profit ₹334.2 Cr, Up 30.9% YoY

Ajanta Pharma Ltd reported revenue from operations of ₹1,626 Cr (+24.8% YoY) and net profit of ₹334.2 Cr (+30.9% YoY) for Q1 FY27.

Key figure

Net profit ₹334.2 Cr · +30.9% YoY

Ajanta Pharma Share Pledge

Ajanta Pharma promoter Aayush Agrawal released a pledge of 21,61,067 shares and simultaneously created a new pledge for the same number of shares.

Ajanta Pharma Board Meeting Date

Ajanta Pharma has scheduled a board meeting for July 30, 2026. The board will consider and approve the Q1 financial results.

Ajanta Pharma Annual General Meeting

Ajanta Pharma concluded its 47th AGM on July 16, 2026. Key resolutions included adopting FY2025-26 financial statements and confirming the interim dividend as final.

Ajanta Pharma Share Pledge

Ajanta Pharma revised its SAST filing, indicating pledged promoter shares as security for non‑convertible debentures. No monetary value of the pledge is disclosed.

Ajanta Pharma Share Pledge

Ajanta Pharma pledged shares as security for debentures totaling ₹3,873 crore. The pledge benefits CTL Trusteeship Ltd as common security trustee.

Value

₹3,873 Cr

Ajanta Pharma Business Update

Ajanta Pharma disclosed that the US FDA inspection of its Paithan facility resulted in a Voluntary Action Indicated classification. The filing is for regulatory update only.

Ajanta Pharma Share Pledge

Promoter Ravi Agrawal Trust released pledges on 17,32,792 equity shares of Ajanta Pharma. The release was executed on June 25, 2026.

Ajanta Pharma Share Pledge

Promoter Aayush Agrawal created a pledge over 1,111,111 Ajanta Pharma shares for a new loan. The pledge increases promoter leverage and warrants monitoring.

Ajanta Pharma Annual General Meeting

Ajanta Pharma's 47th AGM will be held on 16 July 2026 via VC/OAVM. The notice and annual report will be dispatched to members.

Ajanta Pharma Promoter Selling

Ravi Agrawal Trust, a promoter of Ajanta Pharma, sold 34,50,000 shares (2.76%) via the open market. This transaction reduces the promoter trust's stake to 10.24%.

Ajanta Pharma Share Pledge

Ajanta Pharma promoter Ravi Agrawal created a pledge on 2,20,000 shares and released 2,60,000 shares. The creation was driven by business re-financing requirements.

Ajanta Pharma Share Pledge

Ajanta Pharma promoter Aayush Agrawal released a pledge on 1,92,500 shares following loan repayment. This reduction in encumbered shares improves the promoter's skin-in-the-game.

Ajanta Pharma Share Pledge

Promoter Aayush Agrawal pledged and released 2,86,213 shares of Ajanta Pharma Limited. The transactions relate to new loan creation and existing loan repayment.

Ajanta Pharma Other Announcement

Ajanta Pharma submitted its Annual Secretarial Compliance Report for the year ended March 2026. This routine regulatory filing confirms adherence to SEBI listing obligations and disclosure requirements.

Ajanta Pharma Earnings Call: Key Takeaways

Ajanta Pharma achieved record FY26 revenue >₹5,000cr and PAT >₹1,000cr, driven by strong US and Africa performance despite Asia supply chain headwinds.

Ajanta Pharma Earnings Call: Key Takeaways

Ajanta Pharma hit major milestones in FY26, surpassing ₹5,000cr revenue and ₹1,000cr PAT, but faces logistics-driven volatility in Asia and rising costs from Middle East conflicts.

Ajanta Pharma Board Meeting Outcome

Ajanta Pharma Limited's board met on May 5, 2026, and approved the re-appointment of Aneja Assurance Pvt. Ltd as Internal Auditor, RA & Co as Cost Auditors, and M/s. R S Sanghai & Associates as Tax Auditors. All appointments are for a 12-month term.

Execution

12 months

Ajanta Pharma Board Meeting Outcome

Ajanta Pharma Ltd's Board approved the re-appointment of Aneja Assurance Pvt. Ltd. as Internal Auditors, RA & Co. as Cost Auditors, and R S Sanghai & Associates as Tax Auditors for FY 2026-27. The appointments were made during the Board meeting held on May 5, 2026.

Execution

FY 2026-27

Ajanta Pharma Employee Stock Options

Ajanta Pharma granted 1,45,000 stock options under its 2019 Incentive Plan. Each option covers one share with an exercise period of three months post-vesting. Additionally, 850 options were cancelled and returned to the ESOP pool. This move aligns employee interests with long-term shareholder value.

Execution

Three months from the date of vesting

Ajanta Pharma Q4 FY26 Results: Net Profit ₹266.7 Cr, Up 18.4% YoY

Ajanta Pharma Ltd reported revenue from operations of ₹1,422 Cr (+21.5% YoY) and net profit of ₹266.7 Cr (+18.4% YoY) for Q4 FY26.

Key figure

Net profit ₹266.7 Cr · +18.4% YoY

Ajanta Pharma Financial Results

Ajanta Pharma Ltd reported its FY 2026 financial results, with annual consolidated revenue crossing ₹5,453 Crore and PAT exceeding ₹1,056 Crore. The company achieved 21% quarterly revenue growth and 18% PAT growth. Branded generics across India, Asia, and Africa remains the core business, contributing 68% of total revenue.

Ajanta Pharma Legal & Regulatory

Ajanta Pharma announced the conclusion of a US FDA inspection at its Paithan facility. The audit, conducted from April 13 to April 21, 2026, ended with five Form-483 observations. The company stated it will respond to the regulator within the stipulated timeline.

Ajanta Pharma Board Meeting Outcome

Ajanta Pharma Ltd has scheduled a Board Meeting on May 5, 2026. The board will primarily consider and approve the audited standalone and consolidated financial results and statements for the quarter and year ended March 31, 2026.